Biomarkers of risk prediction
Developing accurate risk prediction models for cancer can reduce the cancer burden through risk reduction programs and improved screening algorithms. We are currently developing and validating risk prediction models for colorectal and lung cancer. We are particularly interested in the relative contribution of circulating biomarkers beyond established lifestyle and clinical factors. Of particular interest are markers of DNA methylation and microRNAs.
Real-world evidence and analytics
We apply novel data analytics to identify and understand optimal treatment and care pathways based on patient and tumor characteristics
Cancer Prevention Studies
We conduct studies aimed at reducing the cancer burden in Canada and abroad by understanding trends in incidence and survival and targeting areas of need for intervention.
The genetics of early-onset breast and colorectal cancers
Our research team is evaluating the genomic landscape of breast and colon tumors that occur in younger aged adults. In particular, we are focused on the mutational landscape of breast cancer in young women under 40 and colorectal cancers under aged 50. We are examining whether the genomic alterations observed in young patients differ from those of the general population of patients and whether novel actionable mutations are present.
The impact of lifestyle and environmental factors on the genome and epigenome - role in cancer
We are currently examining the impacts of physical activity and excess body weight on epigenetic and genomic biomarkers.